z-logo
Premium
Raloxifene pharmacokinetics in males with normal and impaired renal function
Author(s) -
Czock David,
Keller Frieder,
Heringa Mette,
Rasche Franz Maximilian
Publication year - 2005
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.2004.02326.x
Subject(s) - raloxifene , pharmacokinetics , confidence interval , medicine , renal function , impaired renal function , urology , creatinine , endocrinology , estrogen receptor , breast cancer , cancer
Aims To compare raloxifene pharmacokinetics between renally impaired and healthy subjects. Methods Raloxifene 120 mg was administered to 10 males with renal impairment (creatinine 2–4 mg dl −1 ) and to 10 healthy males. Data were analysed by two noncompartmental and one compartmental nonlinear regression methods. Results The medians (95% confidence interval) of the area under the curves (AUC) were 35.1 (25.8, 74) and 20.5 (16.8, 28.0) h ng ml −1 per mg kg −1 , P  < 0.01, and of the clearances (CL/F) were 28.5 (13.5, 38.8) and 48.8 (35.8, 59.4) l h −1 kg −1 , P  < 0.01, in renally impaired and healthy subjects, respectively. 95% Confidence intervals on the differences for AUC and CL/F were 6.5–44.1 and −35.1 to −7.9, respectively. Conclusion Exposure to raloxifene was twice as high in males with renal impairment compared with healthy subjects.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here